IP Library › Patent Application 11933912
Patent Application
App. No. 11/933,912

FORMULATION FOR CONTROLLED RELEASE OF DRUGS BY COMBINING HYDROPHILIC AND HYDROPHOBIC AGENTS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/933,912
Abstract

Combinations of hydrophilic and hydrophobic entities in a biodegradable sustained release implant are shown to modulate each other's rate of release. Formulations of a therapeutically active agent and modulator provide substantially constant rate of release for an extended period of time.

Claims (8)

1 . A method for treating an ocular condition, the method comprising the step of implanting in the vitreal chamber of a patient's eye a sustained release device comprising a polymeric matrix and a corticosteroid, the corticosteroid being homogeneously distributed throughout the polymeric matrix, wherein the sustained release device has a shape selected from the group of shapes consisting of fibers and discs, the sustained release device is not a microcapsule, and the sustained release device is dimensioned for implantation in the vitreal chamber of a patient's eye.

2 . The method of claim 1 , wherein the corticosteroid is selected from the group consisting of dexamethasone, hydrocortisone, cortisone, prednisolone, prednisone, progesterone-like compounds, medrysone and fluorometholone.

3 . The method of claim 1 , wherein the corticosteroid is released with about zero order kinetics.

4 . The method of claim 1 wherein the polymer matrix is biodegradable.

5 . The method of claim 1 , wherein the sustained release device which is extruded.

6 . A method for treating an ocular condition, the method comprising the step of implanting in the vitreal chamber of a patient's eye a sustained release device comprising a polymeric matrix and dexamethasone, the dexamethasone being homogeneously distributed throughout the polymeric matrix, wherein the sustained release device has a shape selected from the group of shapes consisting of fibers and discs, the sustained release device is not a microcapsule, and the sustained release device is dimensioned for implantation in the vitreal chamber of a patient's eye.

7 . The method of claim 6 wherein the polymeric matrix is biodegradable.

8 . The method of claim 6 wherein the sustained release device is extruded.